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A B S T R A C T
Purpose
The clinical impact of positron emission tomography (PET) evaluation performed early during first-
line therapy in patients with advanced-stage Hodgkin lymphoma, in terms of providing a rationale to
shift patients who respond poorly onto a more intensive regimen (PET response-adapted therapy),
remains to be confirmed.
Patients and Methods
The phase II part of the multicenter HD0801 study involved 519 patients with advanced-stage de
novo Hodgkin lymphomawho received an initial treatment with doxorubicin, bleomycin, vinblastine,
and dacarbazine (ABVD) and who underwent an early ifosfamide-containing salvage treatment
followed by stem-cell transplantation if they showed a positive PET evaluation after two cycles of
chemotherapy (PET2). The primary end point was 2-year progression-free survival calculated for both
PET2-negative patients (who completed a full six cycles of ABVD treatment) and PET2-positive
patients. Overall survival was a secondary end point.
Results
In all, 103 of the 512 evaluable patientswere PET2 positive. Among them, 81 received the scheduled
salvage regimen with transplantation, 15 remained on ABVD (physician’s decision, mostly because
of minimally positive PET2), five received an alternative treatment, and two were excluded because
of diagnostic error. On intention-to-treat analysis, the 2-year progression-free survival was 76% for
PET2-positive patients (regardless of the salvage treatment they received) and 81% for PET2-
negative patients.
Conclusion
Patients with advanced-stage Hodgkin lymphoma for whom treatment was at high risk of failing
appear to benefit from early treatment intensification with autologous transplantation, as indicated
by the possibility of successful salvage treatment in more than 70% of PET2-positive patients
through obtaining the same 2-year progression-free survival as the PET2-negative subgroup.
J Clin Oncol 34:1376-1385. © 2016 by American Society of Clinical Oncology
INTRODUCTION
Recently, several studies have clearly demonstrated
the predictive value of a positron emission
tomography (PET) scan performed after two cycles
of chemotherapy (ie, interim or PET2) in patients
with advanced-stage Hodgkin lymphoma (HL).1-6
In parallel, large cohort studies have pointed out
several well-established pretreatment prognostic
factors, although it is still the disease stage that
largely determines the initial treatment strategy.7-9
Approximately 65% to 70% of patients with
advanced-stage HL can be cured with six to eight
cycles of doxorubicin, bleomycin, vinblastine, and
dacarbazine (ABVD), with or without con-
solidation radiotherapy.10,11 Escalated bleomycin,
etoposide, doxorubicin, cyclophosphamide, vin-
cristine, procarbazine, and prednisone (BEACOPP)
cures around 85% of patients if given as first-line
therapy, but concerns regarding its acute toxicity
and the possible onset of second myeloid neoplasia
are limiting factors for its widespread use.12,13
1376 © 2016 by American Society of Clinical Oncology
VOLUME 34 • NUMBER 12 • APRIL 20, 2016
Downloaded from ascopubs.org by 130.192.248.36 on January 30, 2018 from 130.192.248.036
Copyright © 2018 American Society of Clinical Oncology. All rights reserved.
Despite an improvement in the therapeutic management of patients
withHL, early identification of those patients inwhom the chances of
cure by conventional treatment are low and for whom an escalated
BEACOPP or an intensified high-dose regimen with a subsequent
peripheral stem-cell autograft can be justified is still a crucial
problem. As it happens with early-stage disease, pretreatment
prognostic tools for advanced-stage disease, notably the International
Prognostic Score (IPS), do not accurately predict which patients will
likely receive a benefit from more intensive therapy.8 A negative
interim PET scan is a strong predictor of favorable outcomes with
standard therapy: long-term progression-free survival (PFS) rates of
approximately 95% have been consistently shown in patients with
advanced-stage HL treated with ABVD who display an early PET
negativity.1-6 Consequently, patients with a poor prognosis can be
identified according to their early response to induction treatment, as
documented by an interim PET evaluation. Therefore, a response-
adapted therapy may be tailored for patients with poor response.
Several trials that take into account a PET response-adapted
therapy for patients with advanced-stage HL are ongoing or have
recently been completed. The common aim of these trials is to de-
escalate therapy in patients with a favorable early PET response or
to escalate therapy in those who do not respond well or to do
both.14-20 The cost-benefit ratio of two different strategies will be
tested by using interim PET as a surrogate indicator for chemo-
therapy sensitivity. The first strategy uses the initiation of first-line
therapy with the most intensive regimen (escalated BEACOPP)
and then de-escalating treatment in patients with a negative
interim PET result. Alternatively, a standard ABVD treatment can
be started and then escalated to either BEACOPP or high-dose
chemotherapy and autologous bone marrow transplantation
(ABMT) only in PET2-positive patients, who can presumably
benefit from an intensified treatment.
Herein we present the final results of the phase II part of an
Italian multicenter trial (HD0801; Early Salvage With High-Dose
Chemotherapy and Stem-Cell Transplantation in Advanced Stage
Hodgkin’s Lymphoma) conducted in centers adhering to the
Italian Lymphoma Foundation guidelines. This phase II trial
included patients with advanced-stage HL that was PET positive
after two cycles of ABVD who were offered a chemotherapy salvage
treatment followed by high-dose chemotherapy with autologous
stem-cell support.
PATIENTS AND METHODS
Study Oversight
HD0801 was a multicenter study involving patients with newly
diagnosed advanced-stage HL, all receiving first-line ABVD treatment and
undergoing a PET2 evaluation. The study will produce an estimate of the
efficacy of an early PET response-adapted strategy in advanced HL. In
addition, this trial was designed to address two specific questions: whether
an early PET-guided salvage treatment consisting of high-dose chemo-
therapy with a subsequent ABMT could be considered safe and effective
compared with data in the literature (phase II; Fig 1, shaded area) and
whether PET2-negative patients could benefit from radiotherapy con-
solidation for areas of bulky disease, provided they maintained PET
negativity upon completion of the planned six ABVD courses (phase III;
Fig 1, white area). The follow-up of the randomized comparison between
patients treated with radiotherapy versus observation is still ongoing;
therefore, results will be reported separately in the future.
The applied salvage treatment (phase II) was made up of four courses
of ifosfamide, gemcitabine, and vinorelbine (IGEV)21 chemotherapy,
which allowed stem-cell mobilization in peripheral blood with harvesting
after the third course,22 and was followed by carmustine, cytarabine,
etoposide, and melphalan (BEAM)–conditioned ABMT treatment if
patients had obtained a PET-documented complete response (CR). In case
of a positive post-IGEV PET evaluation, patients with an HLA-matched
donor were scheduled to receive high-dose melphalan-conditioned ABMT
followed by a reduced-intensity allogeneic transplantation; conversely,
those lacking an HLA-matched donor received high-dose melphalan
ABMT followed by a BEAM-conditioned treatment.
Patient Enrollment and Study Conduct
Patients age 18 to 70 years were considered eligible if they had previously
untreated and histologically documented HL (with the exception of
nodular lymphocyte–predominant subtype) in clinical stage IIB to IVaccording
to Ann Arbor staging and at least one bidimensionally measurable target lesion
(even if extranodal only). Patients were excluded from the study if they had a
severe disease that impaired normal life, presented an active infection, or had an
inadequate liver or renal function, unless this was a result of the lymphoma.
Those with a history of previous malignancy (except basal cell skin carcinoma
and in situ carcinoma of the cervix) were considered ineligible.
Responses were primarily evaluated by centrally reviewed PETscan after
two cycles of ABVD and at the end of the scheduled treatment plan, provided
that all patients had undergone a complete staging workup, including PET
examination, before the start of treatment. The depth of response was graded
according to the revised response criteria for malignant lymphomas.23
All local ethic committees at each center approved the study protocol
and its amendments, in accordance with the Italian law and in compliance
with the Declaration of Helsinki. Patients provided written informed
consent before being included in the study.
Central PET Review
In this study, central PET review played a pivotal role in reducing the
variability of visual scan interpretation between various readers, because
treatment decisions were made on the basis of the result of PET2 scans. PET
scans were interpreted according to Juweid’s criteria,24 which usedmediastinal
uptake as a reference. Central review of all uncertain results took place within
5 days of the PETscan at a central imaging core laboratory at the University of
Florence; a panel of 11 nuclear medicine physicians served as reviewers for all
procedures. The reviewing process proceeded as follows: first, a local nuclear
medicine physician sent the initial and interim PET scans to the core labo-
ratory along with the available clinical information; then, an answer from five
reviewers was sent to the study data center and to local physicians. In case of
discrepancy between the local PETevaluation and the central review, the result
of the latter was considered predominant. All PET2-positive scans were
reviewed at the end of the trial and were interpreted by using the Deauville25
criteria, now regarded as the standard criteria for PET interpretation. These
criteria were elaborated and published while the study was ongoing.
End Points
The primary end point of the phase II part of the study was 2-year PFS
calculated from the date of the PET2 scan to the date of lymphoma pro-
gression, death as a result of any cause, or completion of the 2 years of follow-
up. Overall survival (OS), defined as the time from PET2 scan until death as a
result of any cause or the date of the last follow-up, was a secondary outcome.
In addition, the estimations of OS and PFS calculated from entry into the
study (registration) until the end of follow-up were provided for the entire
study population. Exploratory analyses of factors predicting response and
toxicity will be performed after a longer follow-up becomes available.
Statistical Analysis
The sample size of the phase II part of the trial has been estimated
according to the Fleming-A’Hern design. The primary efficacy end point
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(2-year PFS) was calculated as the cumulative proportion of patients alive and
progression free at 2 years. All other time-to-event end points included in the
study have been estimated by using the Kaplan-Meier method. For all point
estimates, the corresponding confidence intervals were also provided.
Baseline patient characteristics were compared according to PET2
positivity by using the Mann-Whitney U test and x2 test (or Fisher’s exact
test, if appropriate) for continuous variables and categorical variables,
respectively. For the safety analyses, frequency of toxicities was reported by
HLA-matched donorNo HLA-matched donor
PositiveNegative
PositiveNegative
Staging: including CT and PET scan
ABVD, two cycles
PET2 evaluation
Optional CT scan
Nonbulky
RT no bulky No RT
PositiveNegative
End of treatment PET evaluation
ABVD, two cycles
ABVD, two cycles
Randomize
Post-IGEV PET evaluationBEAM-conditioned ABMT
High-dose melphalan
BEAM-conditioned ABMT
Reduced-intensity alloBMT
High-dose melphalan
PET2 positive
IGEV, four cycles
Salvage treatment
Post-IGEV PET evaluation
Off study
Fig 1. Study outline. The shaded area
indicates the phase II part of the study.
ABMT, autologous bone marrow trans-
plantation; ABVD, doxorubicin, bleomycin,
vinblastine, and dacarbazine; alloBMT, allo-
geneic bone marrow transplantation; BEAM,
carmustine, cytarabine, etoposide, and
melphalan; CT, computed tomography;
IGEV, ifosfamide, gemcitabine, and vinor-
elbine; PET, positron emission tomography;
PET2, PET scan performed after two cycles
of chemotherapy; RT, radiotherapy.
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type and grade according to the National Cancer Institute Common
Terminology Criteria for Adverse Events (version 2.0). All analyses were
performed by using STATA version 11.1 (STATA, College Station, TX).
RESULTS
In all, 520 patients who had enrolled onto the study started ABVD
treatment between September 2008 and April 2013 in 50 Italian
centers. Of those patients, 512 (99%) underwent a PET2 scan, one
patient withdrew consent before therapy, and seven patients
interrupted the treatment before the end of the second ABVD
cycle. The demographic and baseline disease characteristics for the
entire population and according to PET2 evaluation are listed
in Table 1.
Median age of the patients was 33 years (range, 18 to 68 years).
Most of the patients (73%) had a nodular sclerosis HL subtype,
46% presented with stage IV disease, and 35% had bulky disease.
The marrow was involved in 49 patients (10%). An IPS $ 3 was
seen in 206 patients (44%).
Response to Treatment
Among the 512 patients with an interim PET2 scan evaluated
by central review, 409 (80%) were PET negative and 103 (20%)
were PET positive. Once the PET2-positive scans had been
reviewed and interpreted by using the Deauville 5-point scale, 70%
had a score $ 4 (and 20% had a score of 5). The remaining 30%
of PET2-positive scans received a score of 3.
As stated by the protocol, all 409 PET2-negative patients
proceeded to four more ABVD cycles, whereas the remaining
patients weremoved to the IGEV salvage arm. However, among the
103 patients with PET2 positivity, 22 did not receive the scheduled
treatment: two because of a diagnostic error and the remaining 20
because of the patients’ refusal to move to high-dose treatment at
that time. Therefore, the latter 20 patients continued the treatment
with four more ABVD cycles (15 patients) or shifted to a different
salvage regimen (five patients). More specifically, among the 15
patients who continued with ABVD therapy, nine presented with a
minimally positive PET2 scan (ie, just above background, which
was compatible with a Deauville score of 3 upon central revision of
the cases, as stated above in Patients andMethods), and one patient
had a false-positive result, as demonstrated by a negative lymph
node biopsy. One patient refused the high-dose treatment and the
transplantation procedure.
Regarding the other 81 PET2-positive patients, all received
four courses of IGEV and were able to provide peripheral blood
stem cells, which allowed them to proceed to subsequent high-dose
chemotherapy with autologous stem-cell support. At the end of
IGEV therapy, 43 patients were PET-negative and underwent
BEAM-conditioned ABMT therapy. Among the 38 patients with a
positive post-IGEV scan, 24 received tandem ABMT therapy, and
11 of them had a PET-negative result at the end of treatment.
Conversely, 14 patients underwent allogeneic transplantation, and
Table 1. Clinical Characteristics of the Patients Who Underwent PET2 Evaluation
Characteristic
PET2 Negative
(n = 409), No. (%)
PET2 Positive
(n = 103), No. (%)
Total
(n = 512), No. (%) P
Median age 33 32 33 .198
Male sex 222 (54) 53 (51) 275 (54) .608
IPS* .996
0-2 209 (56) 52 (56) 261 (56)
$ 3 165 (44) 41 (44) 206 (44)
Histology .520
Nodular sclerosis 292 (71) 80 (78) 372 (73)
Mixed cellularity 60 (15) 11 (11) 71 (14)
Lymphocyte depletion 10 (2) 1 (1) 11 (2)
Lymphocyte rich 18 (4) 2 (2) 20 (4)
Unspecified 29 (7) 9 (9) 38 (7)
No systemic symptoms 144 (35) 42 (41) 186 (36) .294
B symptoms 265 (65) 61 (59) 326 (64)
LDH increase 129 (32) 37 (36) 166 (32) .396
Performance status .966
0 271 (66) 68 (66) 339 (66)
1 112 (27) 30 (29) 142 (28)
2 26 (6) 4 (4) 30 (6)
3 0 (0) 1 (1) 1 (0)
Ann Arbor stage .810
II 80 (20) 19 (18) 99 (19)
III 145 (35) 34 (33) 179 (35)
IV 184 (45) 50 (49) 234 (46)
Bulky disease 143 (35) 38 (37) 181 (35) .714
Extranodal involvement 182 (44) 54 (52) 236 (46) .149
Marrow involvement† 37 (9) 12 (12) 49 (10) .454
Abbreviations: IPS, International Prognostic Score; LDH, lactate dehydrogenase; PET2, positron emission tomography scan performed after two cycles of
chemotherapy.
*Unavailable data in 45 patients (9%).
†Unavailable data in 12 patients (2%).
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four were PET negative after treatment. Twenty-three patients
(28%) were still PET-positive at the end of the entire therapeutic
course (as can be extrapolated from Fig 2).
Among the 15 patients who completed the induction phase
with ABVD, 11 (73%) obtained a CR; four patients achieved the
CR after consolidation radiotherapy. One patient achieved a
partial response (PR) and then received high-dose chemo-
therapy with stem-cell rescue and obtained a final CR; the
remaining three patients relapsed or progressed. No follow-up
data are available for the five patients who were shifted to a
different treatment plan because they withdrew consent for the
study.
Patients were compliant with follow-up procedures, and all
scheduled computed tomography (CT) and PET scans were per-
formed at the correct time points, with a tolerance of 7 days. No
PET protocol violations occurred.
Enrolled
(N = 520)
Treated with ABVD, two cycles
(n = 519)
PET2 evaluable patients
(n = 512)
PET2-positive patients
(n = 103)
Negative patients
(n = 43)
Positive patients
(n = 38)
Consent withdrawal
(n = 1)
Treatment interruptions
(n = 7)
PET2-negative patients 
proceeded to four or 
more cycles of ABVD
(n = 409)
Patients proceeded to 
IGEV salvage
(n = 81)
Patients refused high-dose 
treatment
(n = 20)
Patients on different 
salvage treatment
(n = 5)
Diagnostic errors
(n = 2)
Complete response   (n = 11)
Partial response        (n = 1)
Disease progression (n = 3)
Patients continued to four 
or more ABVD cycles
(n = 15)
BEAM-conditioned ABMT
High-dose melphlan 
BEAM-conditioned ABMT 
(no HLA-matched donor)
(n = 24)
High-dose melphalan
reduced-intensity alloBMT
(HLA-matched donor)
(n = 14)
PET-negative patients
(n = 11)
Negative patients
(n = 43)
PET-negative patients
(n = 4)
Fig 2. Patient flow diagram. ABMT, autologous bone marrow transplantation; ABVD, doxorubicin, bleomycin, vinblastine, and dacarbazine; alloBMT, allogeneic bone
marrow transplantation; BEAM, carmustine, cytarabine, etoposide, and melphalan; IGEV, ifosfamide, gemcitabine, and vinorelbine; PET2, positron emission tomography
scan performed after two cycles of chemotherapy.
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Survival Analysis
Overall, 97 patients experienced disease progression (21 in the
PET2-positive group, 73 in the PET2-negative group, three in
the group of patients without PET2), and 18 patients died (eight in
the PET2-positive group: lymphoma [n = 4], heart failure [n = 1],
viral encephalitis [n = 1], graft-versus-host disease [n = 2]; nine in
the PET2-negative group: lymphoma [n = 3], pneumonia [n = 1],
septic shock [n = 1], lung infection [n = 2], secondary neoplasm [n =
1], graft-versus-host disease [n = 1]; and one in the group of patients
without a PET2 scan who died as a result of lymphoma).
After a median follow-up of 27 months from enrollment, the
Kaplan-Meier estimates for the entire population (calculated from
entry onto the trial) are 97% (95%CI, 94% to 98%) for 2-yearOS (Fig
3A) and 80% (95% CI, 76% to 83%) for 2-year PFS (Fig 3B). On an
intention-to-treat analysis, after a median follow-up of 25 months
from PET2 scanning, the 2-year PFS for the PET2-negative patients
planned to receive six courses of ABVD was 81% (95% CI, 76% to
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Fig 3. (A) Overall survival and (B) progression-free survival for the entire study
population, as determined from the time of enrollment.
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Fig 4. (A) Progression-free survival on an intention-to-treat basis for PET 2-positive
(dashed line; n = 101) and PET2-negative (solid line; n = 409) patients who received
either IGEV chemotherapy and transplantation or an alternative salvage treatment
(including four more ABVD cycles). (B) Progression-free survival for PET2-negative
patients (n=409, solid line), all of whom were scheduled to receive six cycles of
ABVD, compared with PET2-positive patients who actually received IGEV chemo-
therapy and transplantation (n=81, dashed line). ABVD, doxorubicin, bleomycin,
vinblastine, and dacarbazine; IGEV, ifosfamide, gemcitabine, and vinorelbine; PET2,
positron emission tomography scan performed after two cycles of chemotherapy.
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84%), whereas the 2-year PFS for the PET2-positive patients (n = 101,
independently from the IGEV, ABVD, or other salvage treatment they
received) was 76% (95% CI, 66% to 84%; Fig 4A). When calculated
for only the 81 PET2-positive patients who received IGEV salvage
treatment, the 2-year PFS was 74% (95% CI, 62% to 82%; Fig 4B).
In an intention-to-treat analysis (independently from the salvage
treatment patients received), we compared PET-negative patients with
PET-positive patients excluding those withDeauville score 3: the 2-year
PFS of the PET-positive group was 75% (95% CI, 57% to 86%; Fig 5).
Toxicity
Among the 81 patients who received the scheduled salvage
procedure, grade 3 and 4 adverse events were primarily
hematologic and directly correlated with the treatment itself. Grade
3 and 4 neutropenia was documented in 11% and 60% of patients,
respectively, and grade 3 and 4 thrombocytopenia was seen in 15%
and 49% of patients, respectively. The incidence of severe anemia
was lower, with grade 3 in 7% of the patients and grade 4 in 10%;
41% of the patients had grade 2 anemia. No treatment toxicity–
related hospitalization or treatment-related deaths occurred.
The most significant grade 3 and 4 extrahematologic adverse
events (documented in at least 10% of the patients) were febrile
neutropenia (grade 3; 31%), mucositis (grade 3; 16%), and bac-
terial infections (grade 3; 12%); all patients recovered rapidly. All
the other grade 3 and 4 adverse events were rare: one grade 4 hepatic
dysfunction and eight grade 3 events (diarrhea [n = 3], dyspnea [n = 2],
hemorrhagic toxicity [n = 1], pulmonary fibrosis [n = 1], and
Table 2. Toxicities
Toxicity
Grade
0 1 2 3 4
No. % No. % No. % No. % No. %
Hematologic 16 20 1 1 6 7 7 9 51 63
Granulocytes 19 23 — — 4 5 9 11 49 60
Hemoglobin 19 23 15 19 33 41 6 7 8 10
Platelets 18 22 4 5 7 9 12 15 40 49
WBC 19 23 — — 6 7 8 10 48 59
Nonhematologic 20 25 5 6 15 19 37 46 4 5
Cardiac 81 100 — — — — — — — —
Supraventricular arrhythmia 81 100 — — — — — — — —
Ventricular arrhythmia 81 100 — — — — — — — —
Ischemia/infarct 81 100 — — — — — — — —
Hypertension 81 100 — — — — — — — —
Hypotension 81 100 — — — — — — — —
Pericarditis 81 100 — — — — — — — —
Pulmonary hypertension 81 100 — — — — — — — —
Valvular defects 81 100 — — — — — — — —
Febrile neutropenia 55 68 — — — — 25 31 1 1
Gastrointestinal 36 44 10 12 20 25 14 17 1 1
Constipation 76 94 4 5 1 1 — — — —
Diarrhea 65 80 4 5 9 11 3 4 — —
Mucosal 36 44 10 12 21 26 13 16 1 1
Hemorrhagic toxicity 79 98 1 1 — — 1 1 — —
Hepatic and/or pancreatic 74 91 1 1 4 5 1 1 1 1
Hepatic dysfunction 74 91 1 1 4 5 1 1 1 1
Pancreatitis 81 100 — — — — — — — —
Infective 59 73 2 2 7 9 11 14 2 2
Bacterial 62 77 1 1 6 7 10 12 2 2
Fungal 78 96 1 1 1 1 1 1 — —
Viral 75 93 2 2 3 4 1 1 — —
Metabolic 80 99 1 1 — — — — — —
Hyperbilirubinemia 81 100 — — — — — — — —
Hyperglycemia 80 99 1 1 — — — — — —
Hyperuricemia 81 100 — — — — — — — —
Hypoglycemia 81 100 — — — — — — — —
Neurologic 81 100 — — — — — — — —
Cranial nerve neuropathy 81 100 — — — — — — — —
Cerebrovascular ischemia 81 100 — — — — — — — —
Motor neuropathy 81 100 — — — — — — — —
Pulmonary 78 96 1 1 — — 2 2 — —
Dyspnea 78 96 1 1 — — 2 2 — —
Pulmonary fibrosis 80 99 — — 1 1 — —
Renal failure 78 96 — — 3 4 — — — —
Vascular 79 98 — — 1 1 1 1 — —
Phlebitis 80 99 — — 1 1 — — — —
Thrombosis/embolism 80 99 — — — — 1 1 — —
Other toxicities 64 79 5 6 9 11 1 1 2 2
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thrombosis [n = 1]). The remaining toxic effects weremild (grade 1 and
2) and transient. A complete list of toxic events is provided in Table 2.
DISCUSSION
Survival rates for patients with HL, even in advanced stages, have
substantially increased over the last few decades. However, a proper
balance between risks and benefits of different treatment strategies
has not yet been achieved, and the key question of whether to use an
intensified chemotherapy for first-line treatment or to reserve it for
high-risk or relapsing patients is still without an answer. The standard
first-line approach is based on the ABVD regimen.10,11 A second-line
treatment with high-dose chemotherapy followed by ABMT is
generally reserved for the 25% of patients who relapse after initial
treatment. An alternative approach consists of trying to cure as many
patients as possible with a more aggressive regimen (ie, escalated
BEACOPP), to be used from the beginning. Systematic review and
network meta-analysis have shown better PFS and OS rates, although
this more intense approach exposes patients to considerable acute
and late chemotherapy-related toxicity.12,13,26 A randomized com-
parison of ABVD and BEACOPP in patients with advanced-stage HL
has recently been reported,10 and its results have led some authors to
conclude that initial therapy may not necessarily be highly aggressive
in all patients because those who relapse may receive subsequent
intensive salvage therapy. Others have pointed out that OS was a
secondary end point in this study and that the study was small
compared with other similar trials.27 At this time, physicians are not
able to predetermine which patients can be cured by ABVD and
which patients will benefit from escalated BEACOPP.
PET is nowconsidered an essential component inHLmanagement
(because it is widely used for disease staging, restaging, and response
evaluation), and the results of an interim PETassessment (generally after
the first two cycles of chemotherapy) may be regarded as a strong
predictor of the final outcome.2-4 This has been proven in several studies
inwhich a PETscan performed after one to three cycles of chemotherapy
(ABVDwas used in all studies) reliably predicted the treatment outcome
in more than 85% to 90% of patients with HL.1-6 Nevertheless, the
clinical impact of the interim response assessment during therapy (in
other words, if a positive interim PET could justify a shift to a more
intensive treatment regimen) remains to be confirmed by the results of
ongoing prospective trials. So far, only three studies have reported on the
impact of PETresponse-adapted therapy in advanced-stageHL; however,
some studies have methodologic flaws (eg, a small number of patients;
use of interim 67Ga scintigraphy in somepatients)with the last trial being
simply a retrospective analysis.14,28,29
What we report here are the results of the first prospective
multicenter interim PET-adapted trial in a cohort of 512 patients with
advanced-stage HL. The percentage of patients showing a positive
PET2 (20%) was similar to that reported in previous studies.4,5 In the
cohort of PET2-negative patients, the 2-year PFSwas 81% (overlapping
with historical controls), whereas in PET2-positive patients, the 2-year
PFS increased from 12% of the historical control to 74% (76% on an
intention-to-treat analysis) of this study.5,10,11,30 One issue in our
study is the group of 15 PET2-positive patients who received four
more ABVD cycles as a result of the physician’s or patient’s refusal to
switch to the salvage treatment program (among the 15 patients, nine
had a minimally positive PET2, which corresponded to Deauville
score 3 upon central revision, and one had a negative biopsy of a PET-
positive lymph node); 73% achieved a CR, thus indicating the
existence of a proportion of patients who can obtain a CR even
though they show PET positivity at early evaluation. As reported in all
published data sets, this percentage ranges between 10% and 30%; in
this study, it is 11%.1,2,4-6 However, the fact that PET results were
assessed qualitatively (the protocol was designed in 2007 before the
Deauville criteriawere formulated25) and that patients with a borderline
PET could have beenmisclassified could represent a potential limitation
of this study. This is why we conducted a post hoc revision of all the
PET2-positive patients using theDeauville criteria to determinewhether
the favorable survival outcome obtained by patients who received a
transplantation depended on a higher proportion of patients with
Deauville score 3 (ie, minimally positive PET 2 scan) being allocated to
this arm, which in fact did not. Nearly 70% of the patients in the
transplantation arm had a Deauville score $ 4. An additional PFS
analysis comparing PET2-negative and PET2-positive patients
(excluding patients with a Deauville score of 3) reported comparable
results, which did not change study outcomes.
To the best of our knowledge, these data support, for the first
time, the role of early treatment intensification in a small proportion
of patients considered at high risk for treatment failure and identified
by PET2 positivity. This strategy is opposed to the conventional
approach of submitting patients to salvage treatment only after they
demonstrate resistance to first-line induction or as soon as the disease
relapses. This is confirmed by the possibility of having more than
70% of the PET2-positive patients receive salvage therapy by
obtaining the same 2-year PFS as the PET2-negative subgroup.
Reversible grade 3 and 4 cytopenias occurred, as previously
reported.21,22 Neither treatment toxicity–related hospitalization nor
treatment-related deaths have been documented so far, thus achieving
a favorable toxicity profile for such an intensive therapeutic strategy.
The most relevant theoretical advantages of this approachmay
be represented by better long-term results because of reduced
resistance to induction treatment and a consequently decreased
incidence of early and late adverse effects. Conversely, the major
disadvantage could be overtreatment of a minority of PET2-
positive patients who could benefit from continuation of the
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Fig 5. Progression-free survival on an intention-to-treat basis. Solid line, PET2-
negative patients; dashed line, PET2-positive patients (Deauville score 4 and 5).
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original treatment plan. Longer follow-up will allow more valid
and robust conclusions for long-term efficacy and toxicity.
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Appendix
Patients and Methods
Patients’ enrollment and study conduct. All patients had their medical history collected at the time of enrollment. Staging
procedures consisted of a full physical examination; a complete blood cell count with leukocyte differential and platelet count; a
computed tomography (CT) scan of neck, chest, abdomen, and pelvis (with and without contrast); an 18F-fluorodeoxyglucose
(FDG) positron emission tomography (PET) scan; and a bone marrow aspiration and biopsy. A mediastinal mass was considered
bulky if its maximum width on a posteroanterior chest x-ray was equal to or greater than one third of the internal transverse
diameter of the thorax at the level of T5/T6; any tumor masses larger than 5 cm at any extramediastinal site were also considered
bulky. Patients were tested for serum creatinine, liver function tests (including hepatitis B virus antigens, and hepatitis C virus
antibodies), uric acid, lactate dehydrogenase, and HIV, and patients had their cardiac function evaluated by echocardiography.
Responses were primarily evaluated by centrally reviewed PETscan after two cycles of doxorubicin, bleomycin, vinblastine, and
dacarbazine (ABVD); further CTand PETevaluation was performed at the end of the sixth cycle of ABVD or, alternatively, after the
fourth ifosfamide, gemcitabine, and vinorelbine (IGEV) course and at the end of any transplantation procedure. The depth of
response was graded according to the revised response criteria for malignant lymphomas.23 A complete response was defined as the
complete disappearance of all detectable clinical evidence of disease and disease-related symptoms, if present before therapy, with
residual masses of any size being permitted if the scan was PET negative. Partial response was defined in case of at least a 50%
decrease in the sum of the products of the diameters (SPD) of up to six dominant masses without any increase in the size of other
nodes, liver, or spleen. Moreover, it was required that splenic and hepatic nodules regressed by at least 50% in their SPD, with the
PET scan still positive in at least one prior involved site. The disease was considered stable if the patient failed to attain the criteria
needed for a complete response or partial response, without fulfilling those for progressive disease. Progressive disease was defined
as the appearance of any new lesion of more than 1.5 cm in any axis, even if other lesions were decreasing in size, or as an increase of
at least 50% in the SPD of any previously involved node (or splenic or hepatic nodes). Any increased PET uptake in a previously
unaffected site required confirmation with other modalities. Follow-up consisted of clinical and laboratory evaluation every
4 months after the end of the treatment program; CT and PET scans were performed yearly for the first 5 years of follow-up.
PET protocol. FDG PET scans were performed with modern full-ring dedicated PET/CT scanners. For each patient, baseline
and follow-up scans were performed at the same nuclear medicine center and with the same instrument. The quality of the studies
was guaranteed by quality control processes at each center by means of daily quality control measures and/or daily setup and/or
tuning and periodical tests of PET performances according to manufacturers’ recommendations and internal procedures.
Inspection of uniformity and quantitative accuracy of the reconstructed image were considered to identify technical failures that
were not detected by using the routine daily quality control procedures. In addition, sinogram data were visually inspected to check
for detector failures. PerformanceMeasurements of Positron Emission Tomographs (National Electrical Manufacturers Association
NU2-2001) were scheduled at each PET site according to local procedures. Maintenance of all the other devices involved (eg, dose
calibrators, well counters, clocks) was performed according to manufacturers’ recommendations.
A dose of approximately 185 to 550 MBq was administered intravenously as a bolus according to routine clinical acquisition
protocol for the specified PET scanner. A whole-body acquisition with attenuation correction and with emission scan was
performed 60 to 90 minutes after injection, starting from the groin up to the ears. The recommended interval between FDG
administration and the start of acquisition is 60 minutes in the latest version of European Association of Nuclear Medicine
Procedures Guidelines (Boellaard, et al: Eur J Nucl Med Mol Imaging 37:181-200, 2010). However, this recommended interval may
change in clinical trials, depending on disease and study aims: times to scan of 60 to 90 minutes, as stated in the study protocol, have
in fact been considered a reasonable interval, given the daily work-up of each center and given that uptake curves seem to become
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flatter at 60 to 90 minutes after injection (Shankar, et al: J Nucl Med 47:1059-1066, 2006; Lowe, et al: J Nucl Med 36:883-887, 1995;
Hutchings, et al: Blood 107:52-59, 2006; Castellucci, et al: Eur J Nucl Med Mol Imaging 32:749-756, 2005). The time for bed
position depended on the PETmachine used and was left open. Scans corrected for decay, body weight, and administered activity
were reconstructed by using iterative algorithms.
PETresults have been scored according to a two-point visual scoring system (0: negative, normal, minimal residual uptake just
below background, benign; 1: positive, malignant). Mediastinal uptake was used as a reference. In addition, all PET2-positive scans
were reviewed by a board of three independent reviewers who were specifically recruited for this purpose to attribute the Deauville
score.25
Statistical analysis. Progression-free survival (PFS) comparison between positive and negative positron emission tomography
evaluation after two cycles of chemotherapy (PET2) patients was performed by using a Cox proportional hazardmodel adjusting for
age, sex, histology, increased lactate dehydrogenase, stage, systemic symptoms, and bulky disease.
Results
Survival analysis. Regarding patients with stage III to IV disease, the 2-year PFS was 79% (95% CI, 74% to 82%) for the entire
population and 76% (95% CI, 65% to 85%) for the PET2-positive patients. In patients with stage II disease, the 2-year PFS was 83%
(95% CI, 73% to 90%) for the entire population and 76% (95% CI, 48% to 90%) for the PET2-positive patients.
© 2016 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Zinzani et al
Downloaded from ascopubs.org by 130.192.248.36 on January 30, 2018 from 130.192.248.036
Copyright © 2018 American Society of Clinical Oncology. All rights reserved.
